$SYRE
Spyre Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022027895 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $174.0K $625.0K $1.362M
YoY Change -87.56% -95.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.952M $7.675M $8.825M
YoY Change 1.65% 12.5% 38.98%
% of Gross Profit
Research & Development $11.98M $15.37M $16.98M
YoY Change -19.36% 13.21% 43.15%
% of Gross Profit
Depreciation & Amortization $401.0K $378.0K $403.0K
YoY Change -2.67% -3.82% 13.52%
% of Gross Profit
Operating Expenses $18.93M $23.05M $25.80M
YoY Change -12.74% 12.97% 41.7%
Operating Profit -$18.76M -$22.42M -$24.44M
YoY Change -7.58% 234.42%
Interest Expense $288.0K $104.0K $35.00K
YoY Change 700.0% 447.37% 75.0%
% of Operating Profit
Other Income/Expense, Net $312.0K $109.0K -$30.00K
YoY Change -1400.0% -430.3% 0.0%
Pretax Income -$18.44M -$22.31M -$24.44M
YoY Change -9.06% 231.17% 34.12%
Income Tax -$209.0K $9.000K $0.00
% Of Pretax Income
Net Earnings -$18.23M -$22.32M -$24.44M
YoY Change -10.21% 226.84% 34.13%
Net Earnings / Revenue -10479.31% -3571.68% -1794.13%
Basic Earnings Per Share -$0.19 -$0.27 -$0.37
Diluted Earnings Per Share -$0.19 -$0.27 -$370.3K
COMMON SHARES
Basic Shares Outstanding 61.17M 82.21M 66.00M
Diluted Shares Outstanding 94.20M 82.21M 66.00M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.68M $88.55M $68.55M
YoY Change -35.52% -32.11% -46.65%
Cash & Equivalents $38.99M $37.47M $16.47M
Short-Term Investments $34.69M $51.08M $52.09M
Other Short-Term Assets $7.874M $7.617M $4.859M
YoY Change 54.82% 31.55% 47.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $82.22M $96.65M $72.60M
YoY Change -30.03% -28.07% -52.05%
LONG-TERM ASSETS
Property, Plant & Equipment $3.555M $3.890M $7.946M
YoY Change -59.66% -57.81% -17.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $749.0K $752.0K $2.628M
YoY Change -72.6% -77.84% 1.08%
Total Long-Term Assets $9.347M $10.06M $10.57M
YoY Change -19.05% -20.24% -13.33%
TOTAL ASSETS
Total Short-Term Assets $82.22M $96.65M $72.60M
Total Long-Term Assets $9.347M $10.06M $10.57M
Total Assets $91.57M $106.7M $83.17M
YoY Change -29.05% -27.4% -49.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.178M $1.958M $2.981M
YoY Change 124.26% -11.84% 56.89%
Accrued Expenses $13.00M $13.61M $11.25M
YoY Change -5.66% 5.91% -0.46%
Deferred Revenue $2.679M $2.663M $2.809M
YoY Change -58.17%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.68M $15.86M $16.30M
YoY Change -13.46% -23.01% -49.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $5.215M
YoY Change -100.0% -100.0% 2431.55%
Total Long-Term Liabilities $0.00 $0.00 $5.215M
YoY Change -100.0% -100.0% 2431.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.68M $15.86M $16.30M
Total Long-Term Liabilities $0.00 $0.00 $5.215M
Total Liabilities $24.01M $22.55M $21.51M
YoY Change -11.0% -19.34% -46.03%
SHAREHOLDERS EQUITY
Retained Earnings -$406.8M -$388.6M -$366.2M
YoY Change 26.57% 29.06% 24.47%
Common Stock $474.5M $472.9M
YoY Change 12.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.56M $84.16M $61.66M
YoY Change
Total Liabilities & Shareholders Equity $91.57M $106.7M $83.17M
YoY Change -29.05% -27.4% -49.17%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$18.23M -$22.32M -$24.44M
YoY Change -10.21% 226.84% 34.13%
Depreciation, Depletion And Amortization $401.0K $378.0K $403.0K
YoY Change -2.67% -3.82% 13.52%
Cash From Operating Activities -$15.07M -$20.67M -$26.26M
YoY Change -11.36% -1092.94% 34.48%
INVESTING ACTIVITIES
Capital Expenditures -$1.000K $0.00 $37.00K
YoY Change -98.92% -100.0% -91.78%
Acquisitions
YoY Change
Other Investing Activities $16.50M $750.0K $25.80M
YoY Change 181.09% -101.58% 164.57%
Cash From Investing Activities $16.50M $750.0K $25.76M
YoY Change 185.6% -101.58% 176.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $42.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -130.0K 42.80M 12.00K
YoY Change -111.37% -22628.42% -96.69%
NET CHANGE
Cash From Operating Activities -15.07M -20.67M -26.26M
Cash From Investing Activities 16.50M 750.0K 25.76M
Cash From Financing Activities -130.0K 42.80M 12.00K
Net Change In Cash 1.301M 22.88M -515.0K
YoY Change -112.91% -150.32% -94.78%
FREE CASH FLOW
Cash From Operating Activities -$15.07M -$20.67M -$26.26M
Capital Expenditures -$1.000K $0.00 $37.00K
Free Cash Flow -$15.07M -$20.67M -$26.30M
YoY Change -10.88% -1078.84% 31.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
20401000
dei Amendment Flag
AmendmentFlag
false
us-gaap Operating Expenses
OperatingExpenses
48851000
us-gaap Operating Expenses
OperatingExpenses
38610000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46959000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25048000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22423000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6705000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
184000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2101000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-13000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46864000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24914000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
104000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
19000
us-gaap Investment Income Net
InvestmentIncomeNet
139000
us-gaap Investment Income Net
InvestmentIncomeNet
41000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24436000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61657000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24956000
CY2022Q2 agle Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
42873000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2017000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46936000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6830000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
84157000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
139832000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
us-gaap Net Income Loss
NetIncomeLoss
-25048000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17448000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
146000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1757000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
480000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
27750000
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93579000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
54296000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
56000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26509000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38059000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82209032
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82209032
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
42979000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65631906
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65631906
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73650146
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73650146
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65618207
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65618207
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6830000
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
184000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
403000
us-gaap Net Income Loss
NetIncomeLoss
-46759000
us-gaap Net Income Loss
NetIncomeLoss
-25048000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
347000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
233000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18218000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
123755000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42816000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2080000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-95000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22294000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-49000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6822000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13176000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
23048000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Central Index Key
EntityCentralIndexKey
0001636282
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61172510
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15142000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4948000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1804000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3806000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49355130
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106707000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
625000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13696000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1987000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13696000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15373000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13579000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32351000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25434000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7675000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
6000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-151000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22390000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6844000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6830000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119024000
us-gaap Profit Loss
ProfitLoss
-46759000
us-gaap Profit Loss
ProfitLoss
-25048000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
781000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
753000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-239000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
405000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
23000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-341000
us-gaap Share Based Compensation
ShareBasedCompensation
4118000
us-gaap Share Based Compensation
ShareBasedCompensation
3837000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
191000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
219000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-336000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-250000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-914000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7804000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-877000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1867000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55326000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16980000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
91937000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39274000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36611000
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
0
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
872000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 agle Working Capital
WorkingCapital
80800000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388600000
CY2022Q2 agle Cash Cash Equivalents Marketable Securities And Restricted Cash
CashCashEquivalentsMarketableSecuritiesAndRestrictedCash
90400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs and revenue recognition.</p>
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
59998000
CY2021Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
41000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
59998000
CY2021Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
41000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
38
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company’s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company’s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers.</p>
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
51080000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
66297000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
29
CY2022Q2 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
10
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
28479000
CY2022Q2 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
7000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28472000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
51263000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
51080000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8888000
CY2021Q4 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8888000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
78024000
CY2022Q2 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
190000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
66297000
CY2022Q2 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
190000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
51080000
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3663000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4988000
CY2022Q2 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
7098000
CY2021Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
5995000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1914000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2264000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
461000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
783000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13136000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14030000
CY2022Q2 agle Class Of Warrant Or Right Offering Price Of Warrants Or Rights
ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
1.5999
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42900000
CY2022Q2 agle Placement Agent Fees And Offering Costs
PlacementAgentFeesAndOfferingCosts
2100000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
0.0499
agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
0.0999
agle Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description
PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription
The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3576000
agle Contract With Customer Liability Revenue Recognized Including Additions
ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions
1074000
agle Contract With Customer Liability Deductions Through Contracts Acquired
ContractWithCustomerLiabilityDeductionsThroughContractsAcquired
1987000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2663000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
dei Local Phone Number
LocalPhoneNumber
942-2935
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Address Address Line1
EntityAddressAddressLine1
805 Las Cimas Parkway
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei City Area Code
CityAreaCode
512
dei Entity Registrant Name
EntityRegistrantName
AEGLEA BIOTHERAPEUTICS, INC.
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4312787
dei Entity File Number
EntityFileNumber
001-37722
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value Per Share
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Trading Symbol
TradingSymbol
AGLE
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
752000
CY2021Q4 us-gaap Assets
Assets
109926000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37470000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3615000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
842000
CY2022Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
479000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
51080000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2359000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
96646000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3890000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
477000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
291000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
98891000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4549000
CY2022Q2 us-gaap Assets
Assets
106707000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14030000
CY2022Q2 us-gaap Liabilities
Liabilities
22550000
CY2021Q4 us-gaap Liabilities
Liabilities
25985000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20144000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4608000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61172510
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3319000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13136000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
815000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7617000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15862000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4316000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2372000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1217000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109926000
us-gaap Net Income Loss
NetIncomeLoss
-46759000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
84157000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
472939000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
425765000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-220000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388568000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341809000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1958000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
140000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22314000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6738000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46724000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
77986000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1838000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61172510
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49355130
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2419000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2876000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1352000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-55000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-155000

Files In Submission

Name View Source Status
0001564590-22-027895-index-headers.html Edgar Link pending
0001564590-22-027895-index.html Edgar Link pending
0001564590-22-027895.txt Edgar Link pending
0001564590-22-027895-xbrl.zip Edgar Link pending
agle-10q_20220630.htm Edgar Link pending
agle-10q_20220630_htm.xml Edgar Link completed
agle-20220630.xsd Edgar Link pending
agle-20220630_cal.xml Edgar Link unprocessable
agle-20220630_def.xml Edgar Link unprocessable
agle-20220630_lab.xml Edgar Link unprocessable
agle-20220630_pre.xml Edgar Link unprocessable
agle-ex311_6.htm Edgar Link pending
agle-ex312_8.htm Edgar Link pending
agle-ex321_9.htm Edgar Link pending
agle-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gq44fyizxb4r000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending